Clinical Trial Update: A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) [Phase 2]

View source ↗

Summary

Phase 2 trial exploring dalotuzumab with irinotecan versus cetuximab with irinotecan in metastatic rectal cancer; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Neoplasms

Drugs mentioned

• Cetuximab (cetuximab)
• Dalotuzumab (dalotuzumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Rectal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2020-05-04